APA (7th ed.) Citation

SD, Z., C, D., MR, G., AM, S., S, A., BL, C., . . . AM, W. (2008). AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Molecular cancer therapeutics, 7(9), 2955. https://doi.org/10.1158/1535-7163.MCT-08-0492

Chicago Style (17th ed.) Citation

SD, Zabludoff, et al. "AZD7762, a Novel Checkpoint Kinase Inhibitor, Drives Checkpoint Abrogation and Potentiates DNA-targeted Therapies." Molecular Cancer Therapeutics 7, no. 9 (2008): 2955. https://doi.org/10.1158/1535-7163.MCT-08-0492.

MLA (9th ed.) Citation

SD, Zabludoff, et al. "AZD7762, a Novel Checkpoint Kinase Inhibitor, Drives Checkpoint Abrogation and Potentiates DNA-targeted Therapies." Molecular Cancer Therapeutics, vol. 7, no. 9, 2008, p. 2955, https://doi.org/10.1158/1535-7163.MCT-08-0492.